Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07019987

Adiposity Distribution in Acute Respiratory Failure

Acute Hypoxemic Respiratory Failure (AHRF) is a condition in which injury to the lungs impairs the ability of the air sacs (alveoli) to ventilate and exchange oxygen. This impairment may be worsened in individuals with elevated body weight, particularly when fat tissue compresses the lungs and promotes alveolar collapse. The impact of body weight on lung function may be greater in individuals with upper-body fat distribution.

Two common interventions for AHRF-positive end-expiratory pressure (PEEP) and prone positioning-are used to improve lung ventilation. However, it is unclear whether these therapies are equally effective across different body weight categories and fat distributions.

This study will evaluate whether body weight and fat distribution affect patients' lung inflation responses to PEEP and prone positioning. Lung inflation will be assessed using electrical impedance tomography (EIT), a bedside imaging tool that maps lung ventilation, and esophageal manometry, which estimates lung compression through a thin catheter placed in the esophagus. Laboratory tests will also be used to measure markers of inflammation and AHRF severity and find correlations with fat distribution and responses to the tested treatments..

Patients with AHRF requiring mechanical ventilation will be enrolled across a range of body weights. Each participant will undergo combinations of two PEEP levels and two body positions (supine and prone) for 30 minutes each. At the end of the study procedures, clinical care will continue as determined by the treating team.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

About this study

This study investigates the relationship between body habitus and the physiological response to ventilatory interventions in patients with Acute Hypoxemic Respiratory Failure (AHRF). The primary objectives are to determine:

  • Whether excess body weight affects the regional lung inflation response to PEEP and prone positioning;
  • Whether body fat distribution (e.g., central vs. peripheral) is associated with lung recruitment;
  • Whether inflation responses correlate with laboratory markers of systemic inflammation and AHRF severity.

Adult patients with AHRF requiring invasive mechanical ventilation will be screened daily in the intensive care units at Massachusetts General Hospital. The study team will coordinate with clinical staff and patient surrogates to obtain informed consent. Enrollment is limited to the period required to perform study-specific procedures. No follow-up visits or post-discharge interventions are planned.

After consent, participants will be equipped with two adhesive EIT electrode belts, placed bilaterally on the thorax, to measure regional ventilation. A pressure and flow sensor will be placed in the breathing circuit at the proximal end of the endotracheal tube. An esophageal balloon catheter will be inserted nasally into the distal esophagus (approximately 35-40 cm) to measure intrathoracic pressure (ITP) via esophageal manometry, recorded through an auxiliary module on the EIT device.

Once all monitoring devices are in place, patients will be evaluated for adequate sedation and ventilator synchrony. Baseline data will be recorded during ventilation at the clinician-selected PEEP level (PEEP_CLIN), including EIT, airway pressure, flow, and ITP signals over 20 consecutive breaths.

Subsequently, a PEEP titration trial will be conducted to identify an individualized PEEP value (PEEP_TIT) that minimizes both alveolar collapse and overdistension, using EIT-based criteria. The patient will then be ventilated at PEEP_TIT for 30 minutes, after which all measurements will be repeated.

Following supine data collection, patients will be transitioned to the prone position using standard clinical protocols, with participation from ICU staff (physicians, nurses, and respiratory therapists) in accordance with institutional practice. Continuous monitoring (including pulse oximetry and arterial blood pressure) will be maintained throughout the repositioning.

After achieving the prone position, a recruitment maneuver will be performed to standardize lung volume history. The EIT belts will then be reconnected, and the patient will be allowed to stabilize for 30 minutes at PEEP_CLIN before measurements are repeated. A second PEEP titration trial will be performed to determine PEEP_TIT in the prone position, followed by another 30-minute stabilization period and repeat data acquisition.

Arterial blood samples (2 mL each) will be obtained at each PEEP level in both positions (four total, 8 mL cumulative) for gas exchange analysis. An additional 10 mL sample will be collected during supine ventilation at PEEP_CLIN for biomarker analysis. Biomarkers of inflammation (e.g., IL-6, TNF-α, C-reactive protein) and adipose tissue-related factors (e.g., adiponectin, leptin, resistin) will be measured.

After study procedures, participants will be returned to the supine position unless otherwise indicated by the clinical team. All subsequent clinical decisions regarding ventilator management or patient positioning will be made by the attending care team.

This study seeks to generate mechanistic insights into how excess body weight and fat distribution affect the physiologic response to standard ventilatory interventions in AHRF, with the goal of informing more individualized approaches to respiratory support.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • AHRF with PaO2/FiO2 <= 300 mmHg) intubated for less than 72 hours
  • Presence of an arterial line for blood gas measurement and blood pressure monitoring
  • 18 years or older

Exclusion criteria

  • Suspected pregnancy, pregnancy or less than six weeks postpartum
  • Younger than 18 years or older than 80 years.
  • Subject enrolled in another interventional research study
  • Presence of pneumothorax
  • Usage of any devices with electric current generation such as pacemaker or internal cardiac defibrillator
  • Preexisting chronic lung disease or pulmonary hypertension
  • Acute cardiac failure causing pulmonary edema
  • Past medical history of lung malignancy or pneumonectomy, or lung transplant
  • Hemodynamic instability, defined as:
  • Persistent systolic blood pressure <90 mmHg and/or >180 mmHg despite the use of vasopressor or vasodilators, or
  • Requiring an increment in inotropic-vasopressors over the past two hours just before enrollment: more than 15 mcg/min for norepinephrine and dopamine, more than 10 mcg/min in epinephrine; and more than 50 mcg/ min for phenylephrine.
  • Contraindications to placement in the prone position: complex abdominal surgical dressing, recent sternotomy, unstable spine or pelvic fractures, intracranial hypertension, serious facial injury
  • Extracorporeal life support

Treatment and study plan

PEEP Titration Using Electrical Impedance Tomography (EIT)

Other

EIT will be used to guide individualized PEEP titration in mechanically ventilated patients with AHRF. Each subject will receive mechanical ventilation at two PEEP levels:

PEEP_CLIN (set by the treating clinician)

PEEP_TIT (identified using EIT to minimize alveolar collapse and overdistension)

Both levels will be maintained for 30 minutes in each body position, with continuous physiologic data collected during each phase.

Body Positioning: Supine and Prone

Procedure

Each subject will be ventilated in both the supine and prone positions. Positioning will follow institutional protocols and be coordinated with clinical staff to ensure safety. After supine assessments are completed, the patient will be transitioned to prone, followed by a recruitment maneuver to standardize lung volume history. The PEEP titration protocol will then be repeated in the prone position.

Primary outcomes

  1. Driving pressure with PEEP titration and prone position

    Time frame: Day 1, after 30 minutes in each combination of PEEP and body position

    The primary outcome will be the difference in driving pressure (inspiratory plateau pressure minus total PEEP, in cmH2O) in response to PEEP titration strategies and to prone position. Changes in driving pressure will be correlated with body mass index, and with measurements of thoracic, and abdominal circumference.

Secondary outcomes

  1. Regional ventilation

    Time frame: Day 1, after 30 minutes in each combination of PEEP and body position

    Changes in EIT-derived measurements of regional ventilation with PEEP titration and prone positioning. EIT regional ventilation is measured as percentage of total ventilation in each examined lung region.

Other outcomes

  1. Age

    Time frame: Day 1

    Age will be measured in years.

  2. Height

    Time frame: Day 1

    Body height will be measured in meters and will be aggregated with body weight to yield body mass index (BMI) in kg/m^2.

  3. Weight

    Time frame: Day 1

    Body weight will be measured in kg and will be aggregated with height to yield body mass index (BMI) in kg/m^2

  4. Thoracic circumference

    Time frame: Day 1

    Thoracic circumference will be measured in cm using a tape ruler placed at nipple level.

  5. Abdominal circumference

    Time frame: Day 1

    Abdominal circumference will be measured in cm using a tape ruler at the level of the umbilicus.

  6. Hip circumference

    Time frame: Day1

    Hip circumference will be measured in cm using a tape ruler placed around the widest portion of the hips.

  7. Comorbidities

    Time frame: Day 1

    The medical record will be reviewed and the presence of the following coexisting conditions will be recorded:

    Hypertension Diabetes Heart failure Liver disease Cancer

  8. APACHE II

    Time frame: First 24 hours since admission

    APACHE II is a severity score (Crit Care Med. 1985 Oct;13(10):818-29.) that will result from the aggregation of the following variables obtained from the medical record on the day of the study:

    age, temperature, mean arterial pressure, pH, heart rate, respiratory rate, plasma sodium, potassium, creatinine, presence of acute renal failure (yes/no), hematocrit, white blood cell count, Glasgow coma scale, and inspired fraction of oxygen (<50%, >=50%).

  9. AHRF etiology

    Time frame: Day 1

    The etiology of AHRF will be recorded from the medical record as a binary variable (pulmonary vs. non pulmonary cause).

  10. Partial Pressure of Oxygen (PaO2)

    Time frame: Day 1, arterial blood gas samples will be taken at 4 time points, after 30 minutes in each combination of PEEP and body position

    The PaO2 will be measured in mmHg in arterial blood samples.

  11. Arterial Partial Pressure of Carbon Dioxide (PCO2)

    Time frame: Day 1, arterial blood gas samples will be taken at 4 time points, after 30 minutes in each combination of PEEP and body position

    The PaCO2 will be measured in mmHg in arterial blood samples.

  12. pH

    Time frame: Day 1, arterial blood gas samples will be taken at 4 time points, after 30 minutes in each combination of PEEP and body position

    The pH will be measured in arterial blood samples.

  13. Bicarbonate

    Time frame: Day 1, arterial blood gas samples will be taken at 4 time points, after 30 minutes in each combination of PEEP and body position

    The plasma bicarbonate will be measured in mEq/l with an arterial blood sample.

  14. Plateau airway pressure

    Time frame: Day 1, after 30 minutes in each combination of PEEP and body position

    Plateau airway pressure will be measured in cmH2O during an inspiratory hold of the ventilator.

  15. Respiratory Rate

    Time frame: Day 1, after 30 minutes in each combination of PEEP and body position

    Respiratory rate will be measured in breaths per minute during tidal ventilation.

  16. Peak inspiratory pressure

    Time frame: Day 1, after 30 minutes in each combination of PEEP and body position

    Peak inspiratory pressure will be measured in cmH2O at the end of a tidal breath by the ventilator.

  17. Total positive end expiratory pressure (PEEPt)

    Time frame: Day 1, after 30 minutes in each combination of PEEP and body position

    PEEPt will be measured in cmH2O during an expiratory hold of the ventilator

  18. Mean Arterial Blood Pressure

    Time frame: Day 1, after 30 minutes in each combination of PEEP and body position

    Mean arterial blood pressure will be measured in mmHg through a preexisting arterial line and recorded by the clinical monitor.

  19. Vasoactive medications (dopamine, dobutamine, epinephrine, levosimendan, milrinone, vasopressin, norepinephrine)

    Time frame: Day 1

    We will calculate the Vasoactive-inotropic score (VIS). The VIS compares different vasoactive-inotropic drugs and doses among the patients. VIS = dopamine dose (mg/kg/min)+ dobutamine [mg/kg/min) +100 x epinephrine dose (mg/ kg/min) +50 x levosimendan dose [mg/kg/min) + 10 x milrinone dose [mg/kg/min)+ 10,000 x vasopressin [units/kg/min) + 100x norepinephrine dose [mg/kg/min) using the maximum dosing rates of vasoactive and inotropic medications. Ref: Koponen et al. British Journal of Anaesthesia, 122 (4): 428e436 (2019). This exploratory outcome plans to combine driving pressure and electrical impedance tomography with other markers (demographical, body metrics, clinical, biochemical, and inflammatory) to identify responses to PEEP and prone positioning.

  20. Life Sustaining Therapies

    Time frame: Day 1

    The presence of the following life sustaining therapy on the day of the study (in addition to mechanical ventilation and vasoactive medications) will be recorded as binary variables (yes/no) from the medical record:

    antibiotics, renal replacement therapy, and artificial nutrition.

  21. Interleukin 6 (IL-6)

    Time frame: Day 1, once

    IL-6 (ng/mL) is an inflammatory biomarker that will be measured in blood samples that will be collected on the day of the study.

  22. C-reactive protein (CRP)

    Time frame: Day 1, once

    CRP (mg/L) is an inflammatory biomarker that will be measured on a blood sample obtained on the day of the study.

  23. Adiponectin

    Time frame: Day 1, once

    Adiponectin (micrograms/mL) is a marker of adipose cell metabolic activity that will be measured in a blood sample obtained on the day of the study.

  24. Leptin

    Time frame: Day 1, once

    Leptin (ng/mL) is a parker of adipose metabolic and proinflammatory activity that will be measured on a blood sample on the day of the study

  25. Resistin

    Time frame: Day 1, once

    Resistin (ng/mL) is a marker of inflammatory activity secreted by adipose tissue, it will be measured in blood samples obtained on the day of the study.

  26. tumor necrosis factor-alpha (TNF-alpha)

    Time frame: Day 1, once

    TNF alpha (picograms/mL) is an inflammatory biomarker that will be meaured in a blood sample obtained the day of the study.

Study contacts

Contact information is provided by the study sponsor or research team.

Lorenzo Berra, MD

CONTACT

[email protected]

617 724 0743

Maurizio F Cereda, MD

CONTACT

[email protected]

16176430987

Sponsors and collaborators

Lead sponsor

Maurizio F. Cereda, MD

Other

Collaborators

  • National Institutes of Health (NIH)

Registry information

Official study title

Imaging the Respiratory Effects of Truncal Adiposity in Acute Hypoxemic Respiratory Failure

Important dates

Study start
2028
Primary completion
2029
Study completion
2030
First posted
Jun 13, 2025
Registry last updated
Jun 13, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.